Insider Trading activities of Synta Pharmaceuticals Corp insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Synta Pharmaceuticals Corp since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Synta Pharmaceuticals Corp since year 2005. Table 2 shows the detailed insider transactions of Synta Pharmaceuticals Corp since 2005. The reporting company's ticker symbol is MDGL. The reporting company's CIK number is 1157601.
The total value of stock buying since 2005 is $90,640,611.
The total value of stock sales since 2005 is $8,567,450.
The total value of stock option exercises since 2005 is $617,010.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Synta Pharmaceuticals Corp (MDGL).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-08 9,100 $145,748 0 $0 0 $0
2015-12 0 $0 4,299,991 $1,671,746 0 $0
2015-11 0 $0 12,714,421 $6,374,476 0 $0
2015-04 6,907,143 $12,087,500 0 $0 0 $0
2014-09 300,000 $923,100 0 $0 0 $0
2014-04 1,250,000 $5,012,500 0 $0 0 $0
2013-11 5,183,333 $19,437,498 0 $0 0 $0
2013-06 3,170,000 $14,447,769 0 $0 0 $0
2013-01 0 $0 0 $0 114,250 $581,304
2012-11 123,100 $852,523 0 $0 0 $0
2012-06 1,073,000 $5,831,525 14,340 $82,455 14,340 $35,706
2012-03 0 $0 13,796 $64,853 0 $0
2012-01 1,136,363 $4,999,997 0 $0 0 $0
2011-12 11,059 $43,727 0 $0 0 $0
2011-11 96,500 $372,556 0 $0 0 $0
2011-09 252,191 $960,699 0 $0 0 $0
2011-08 147,309 $549,640 0 $0 0 $0
2011-04 1,581,493 $7,733,498 20,000 $116,000 0 $0
2011-03 5,000 $22,250 28,708 $151,207 0 $0
2010-09 100,000 $363,915 0 $0 0 $0
2010-08 3,514 $10,287 4,000 $12,840 0 $0
2010-06 278,733 $897,989 0 $0 0 $0
2010-01 772,222 $3,474,999 0 $0 0 $0
2009-08 70,000 $200,350 0 $0 0 $0
2009-01 0 $0 15,173 $93,873 0 $0
2008-08 143,397 $1,067,232 0 $0 0 $0
2008-05 80,000 $567,099 0 $0 0 $0
2007-11 5,000 $39,140 0 $0 0 $0
2007-06 70,467 $594,070 0 $0 0 $0
2007-02 1,000,500 $10,005,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Synta Pharmaceuticals Corp insiders (MDGL)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-08-23 Levy Richard S Buy 2,000 16.14 32,280
2017-08-22 Levy Richard S Buy 3,550 16.09 57,112
2017-08-21 Levy Richard S Buy 3,550 15.88 56,356
2015-12-14 Gollust Keith R Sale 300,000 .32 96,600
2015-12-11 Gollust Keith R Sale 300,000 .37 111,000
2015-12-09 Gollust Keith R Sale 145,892 .38 55,293
2015-12-08 Kovner Bruce Sale 1,369,639 .37 506,766
2015-12-08 Gollust Keith R Sale 300,000 .38 114,000
2015-12-07 Kovner Bruce Sale 100 .41 41
2015-12-07 Gollust Keith R Sale 300,000 .39 115,800
2015-12-04 Kovner Bruce Sale 153,607 .41 63,286
2015-12-03 Kovner Bruce Sale 262,434 .41 108,647
2015-12-02 Kovner Bruce Sale 687,603 .43 293,606
2015-12-01 Kovner Bruce Sale 480,716 .43 206,707
2015-11-30 Kovner Bruce Sale 640,505 .43 277,979
2015-11-27 Kovner Bruce Sale 934,595 .49 462,624
2015-11-25 Kovner Bruce Sale 1,503,720 .49 733,815
2015-11-24 Kovner Bruce Sale 538,129 .44 237,314
2015-11-23 Kovner Bruce Sale 635,453 .44 277,692
2015-11-20 Kovner Bruce Sale 230,283 .44 102,015
2015-11-19 Kovner Bruce Sale 1,174,651 .48 559,133
2015-11-18 Kovner Bruce Sale 108,154 .43 46,830
2015-11-17 Kovner Bruce Sale 700,618 .42 295,660
2015-11-17 Gollust Keith R Sale 100,000 .41 41,400
2015-11-16 Kovner Bruce Sale 15,530 .43 6,755
2015-11-13 Kovner Bruce Sale 507,788 .43 219,364
2015-11-12 Kovner Bruce Sale 733,564 .47 347,709
2015-11-11 Kovner Bruce Sale 1,080,941 .50 538,308
2015-11-10 Kovner Bruce Sale 1,397,114 .55 769,809
2015-11-10 Gollust Keith R Sale 188,322 .55 103,012
2015-11-09 Kovner Bruce Sale 2,225,054 .61 1,355,057
2015-04-06 Kovner Bruce Buy 6,857,143 1.75 12,000,000
2015-04-06 Wilson Robert N Buy 50,000 1.75 87,500
2014-09-30 Kovner Bruce Buy 300,000 3.08 923,100
2014-04-11 Kovner Bruce Buy 1,250,000 4.01 5,012,500
2013-11-13 Bahcall Safi R (President and CEO) Buy 20,000 3.75 75,000
2013-11-13 Kovner Bruce Buy 5,000,000 3.75 18,750,000
2013-11-13 Gollust Keith R Buy 150,000 3.75 562,500
2013-11-13 Reardon William S Buy 13,333 3.75 49,998
2013-06-28 Bahcall Safi R (President and CEO) Buy 10,000 5.03 50,300
2013-06-27 Kovner Bruce Buy 150,000 4.71 706,500
2013-06-26 Kovner Bruce Buy 300,000 4.65 1,395,899
2013-06-25 Kovner Bruce Buy 200,000 4.35 869,400
2013-06-24 Kovner Bruce Buy 200,000 4.43 886,000
2013-06-21 Bahcall Safi R (President and CEO) Buy 20,000 4.12 82,380
2013-06-21 Kovner Bruce Buy 50,000 4.23 211,500
2013-06-18 Kovner Bruce Buy 200,000 4.00 799,200
2013-06-14 Bahcall Safi R (President and CEO) Buy 10,000 4.05 40,550
2013-06-06 Bahcall Safi R (President and CEO) Buy 10,000 4.04 40,390
2013-06-06 Kovner Bruce Buy 738,900 4.31 3,186,875
2013-06-05 Vukovic Vojo (SVP, Chief Medical Officer) Buy 10,000 4.58 45,800
2013-06-05 Kovner Bruce Buy 756,000 4.71 3,561,516
2013-06-04 Kovner Bruce Buy 505,100 4.99 2,521,459
2013-06-04 Wilson Robert N Buy 10,000 5.00 50,000
2013-01-23 Gollust Keith R Option Ex 114,250 5.09 581,304
2012-11-14 Kovner Bruce Buy 21,000 6.95 146,012
2012-11-12 Bahcall Safi R (President and CEO) Buy 10,000 7.12 71,200
2012-11-12 Kovner Bruce Buy 54,400 6.89 374,870
2012-06-29 Vukovic Vojo (SVP, Chief Medical Officer) Buy 3,000 5.58 16,755
2012-06-29 Bahcall Safi R (President and CEO) Buy 10,000 5.34 53,370
2012-06-29 Kovner Bruce Buy 910,000 5.45 4,959,500
2012-06-29 Gollust Keith R Buy 150,000 5.35 801,900
2012-06-18 Rieder Wendy E (VP, IP and Legal, Gen. Counsel) Sale 7,170 6.00 43,020
2012-06-18 Rieder Wendy E (VP, IP and Legal, Gen. Counsel) Option Ex 7,170 2.49 17,853
2012-06-04 Rieder Wendy E (VP, IP and Legal, Gen. Counsel) Sale 7,170 5.50 39,435
2012-06-04 Rieder Wendy E (VP, IP and Legal, Gen. Counsel) Option Ex 7,170 2.49 17,853
2012-03-01 Vukovic Vojo (SVP, Chief Medical Officer) Sale 2,555 4.70 12,005
2012-03-01 Koya Keizo (Sr. VP, Drug Development) Sale 6,844 4.70 32,187
2012-03-01 Ehrlich Keith S (VP, Fin. and Admin., CFO) Sale 4,397 4.70 20,661
2012-01-06 Kovner Bruce Buy 1,136,363 4.40 4,999,997
2011-12-07 Kovner Bruce Buy 11,059 3.95 43,727
2011-11-29 Kovner Bruce Buy 8,844 3.96 35,022
2011-11-25 Kovner Bruce Buy 25,016 3.94 98,462
2011-11-23 Kovner Bruce Buy 7,547 3.98 30,037
2011-11-22 Kovner Bruce Buy 453 3.96 1,792
2011-11-21 Kovner Bruce Buy 33,640 3.84 129,312
2011-11-18 Kovner Bruce Buy 21,000 3.71 77,931
2011-09-12 Kovner Bruce Buy 43,085 3.82 164,455
2011-09-09 Kovner Bruce Buy 110,149 3.77 415,702
2011-09-06 Kovner Bruce Buy 50,400 3.79 191,268
2011-09-02 Vukovic Vojo (SVP, Chief Medical Officer) Buy 2,188 4.00 8,752
2011-09-02 Kovner Bruce Buy 46,057 3.89 179,253
2011-09-01 Vukovic Vojo (SVP, Chief Medical Officer) Buy 312 4.07 1,269
2011-08-26 Kovner Bruce Buy 100 3.85 385
2011-08-23 Kovner Bruce Buy 5,167 3.72 19,226
2011-08-22 Kovner Bruce Buy 10,597 3.77 39,961
2011-08-18 Kovner Bruce Buy 3,303 3.79 12,511
2011-08-10 Kovner Bruce (Director) Buy 33,978 3.70 125,582
2011-08-09 Kovner Bruce (Director) Buy 52,464 3.71 194,641
2011-08-08 Kovner Bruce (Director) Buy 41,700 3.77 157,334
2011-04-25 Koya Keizo (Sr. VP, Drug Development) Sale 10,000 6.00 60,000
2011-04-20 Koya Keizo (Sr. VP, Drug Development) Sale 10,000 5.60 56,000
2011-04-14 Kovner Bruce Buy 1,431,493 4.89 7,000,000
2011-04-14 Gollust Keith R Buy 100,000 4.89 488,999
2011-04-14 Wilson Robert N Buy 50,000 4.89 244,499
2011-03-15 Bahcall Safi R (President and CEO) Buy 5,000 4.45 22,250
2011-03-01 Vukovic Vojo (SVP, Chief Medical Officer) Sale 2,617 5.32 13,927
2011-03-01 Koya Keizo (Sr. VP, Drug Development) Sale 18,270 5.23 95,552
2011-03-01 Ehrlich Keith S (VP, Fin. and Admin., CFO) Sale 2,537 5.50 13,966
2011-03-01 Rieder Wendy E (VP, IP and Legal, Gen. Counsel) Sale 5,284 5.25 27,762
2010-09-15 Kovner Bruce Buy 24,264 3.64 88,418
2010-09-14 Kovner Bruce Buy 38,836 3.70 143,654
2010-09-13 Kovner Bruce Buy 36,900 3.57 131,843
2010-08-16 Vukovic Vojo (SVP, Chief Medical Officer) Buy 2,800 2.95 8,260
2010-08-12 Vukovic Vojo (SVP, Chief Medical Officer) Buy 714 2.84 2,027
2010-08-05 Bailey Michael P (Sr. VP, Chief Comm. Officer) Sale 4,000 3.21 12,840
2010-06-15 Kovner Bruce Buy 65,466 3.91 256,102
2010-06-14 Kovner Bruce Buy 2,075 3.42 7,104
2010-06-11 Kovner Bruce Buy 59,400 3.22 191,030
2010-06-10 Bahcall Safi R (President and CEO) Buy 10,000 3.05 30,530
2010-06-10 Kovner Bruce Buy 26,500 3.00 79,447
2010-06-09 Kovner Bruce Buy 88,532 2.92 258,956
2010-06-08 Kovner Bruce Buy 26,760 2.80 74,820
2010-01-08 Bahcall Safi R (President and CEO) Buy 22,222 4.50 99,999
2010-01-08 Kovner Bruce Buy 550,000 4.50 2,475,000
2010-01-08 Gollust Keith R Buy 100,000 4.50 450,000
2010-01-08 Wilson Robert N Buy 100,000 4.50 450,000
2009-08-24 Koya Keizo (Sr. VP, Drug Development) Buy 10,000 2.84 28,430
2009-08-06 Chen Lin Huey Buy 20,000 2.88 57,600
2009-08-06 Bahcall Safi R (President and CEO) Buy 20,000 2.84 56,720
2009-08-06 Chen Lan Bo Buy 20,000 2.88 57,600
2009-01-05 Chadwick Jeremy G (Sr. VP, Pgm Mgmt and Clin Ops) Sale 4,573 6.20 28,370
2009-01-05 Ehrlich Keith S (VP, Fin. and Admin., CFO) Sale 5,600 6.18 34,619
2009-01-05 Rieder Wendy E (VP, IP and Legal, Gen. Counsel) Sale 5,000 6.18 30,884
2008-08-13 Gollust Keith R Buy 31,997 7.78 248,808
2008-08-12 Kovner Bruce Buy 1,300 7.37 9,579
2008-08-12 Gollust Keith R Buy 35,000 7.58 265,230
2008-08-11 Kovner Bruce Buy 25,100 7.15 179,465
2008-08-11 Gollust Keith R Buy 50,000 7.28 364,150
2008-05-30 Gollust Keith R Buy 5,939 7.10 42,160
2008-05-29 Gollust Keith R Buy 24,061 7.18 172,709
2008-05-19 Gollust Keith R Buy 10,000 6.95 69,470
2008-05-16 Gollust Keith R Buy 40,000 7.07 282,760
2007-11-26 Bahcall Safi R (President and CEO) Buy 5,000 7.83 39,140
2007-06-11 Kovner Bruce (Director) Buy 34,600 8.57 296,625
2007-06-08 Kovner Bruce (Director) Buy 35,867 8.29 297,445
2007-02-09 Williams Martin D (Sr. VP, Business Dev., CBO) Buy 200 10.00 2,000
2007-02-09 Jacobson Eric W (Sr. VP, Research and CMO) Buy 300 10.00 3,000
2007-02-09 Kovner Bruce Buy 720,000 10.00 7,200,000
2007-02-09 Gollust Keith R Buy 180,000 10.00 1,800,000
2007-02-09 Wilson Robert N Buy 100,000 10.00 1,000,000

Insider trading activities including stock purchases, stock sales, and option exercises of MDGL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Synta Pharmaceuticals Corp (symbol MDGL, CIK number 1157601) see the Securities and Exchange Commission (SEC) website.